Joseph Schwartz
Stock Analyst at Leerink Partners
(2.27)
# 1,537
Out of 4,667 analysts
142
Total ratings
31.46%
Success rate
1.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $17.39 | +130.02% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $8.93 | +56.77% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $3.01 | +32.89% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.06 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $5.11 | +134.83% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $3.49 | +129.23% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $1.42 | +322.54% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.49 | +311.78% | 5 | Mar 14, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.36 | -26.47% | 4 | Feb 9, 2024 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $5.48 | +9.49% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $39.36 | +21.95% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $20.51 | -12.24% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $9.05 | +120.99% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $33.75 | +0.74% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $61.97 | +109.78% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $106.62 | +50.07% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $124.44 | +30.99% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $0.71 | +1,298.99% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $4.47 | +638.26% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $8.13 | +47.60% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $45.13 | +139.31% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $73.72 | -32.18% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $55.17 | -29.31% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.92 | +108.33% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $31.51 | -4.79% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $43.25 | +15.61% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $38.65 | -22.38% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $5.82 | +862.20% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.52 | +47.06% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $3.60 | +233.33% | 2 | Sep 26, 2017 |
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $17.39
Upside: +130.02%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $8.93
Upside: +56.77%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $3.01
Upside: +32.89%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.06
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.11
Upside: +134.83%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $3.49
Upside: +129.23%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $1.42
Upside: +322.54%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.49
Upside: +311.78%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.36
Upside: -26.47%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $5.48
Upside: +9.49%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $39.36
Upside: +21.95%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $20.51
Upside: -12.24%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $9.05
Upside: +120.99%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $33.75
Upside: +0.74%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $61.97
Upside: +109.78%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $106.62
Upside: +50.07%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $124.44
Upside: +30.99%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $0.71
Upside: +1,298.99%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $4.47
Upside: +638.26%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $8.13
Upside: +47.60%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $45.13
Upside: +139.31%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $73.72
Upside: -32.18%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $55.17
Upside: -29.31%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.92
Upside: +108.33%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $31.51
Upside: -4.79%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $43.25
Upside: +15.61%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $38.65
Upside: -22.38%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $5.82
Upside: +862.20%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.52
Upside: +47.06%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $3.60
Upside: +233.33%